Evidence map›Paper›PMID 25384570›Full record

SynthesisJournal of endocrinological investigation2015

Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology.

A M Isidori, G Balercia, A E Calogero, G Corona, A Ferlin, S Francavilla, D Santi, M Maggi

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of endocrinological investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 7 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 7 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Article
  9. Review
  10. Skeletal Muscle Evaluation in Patients With Acromegaly.Journal of the Endocrine Society · 2024
    Review
  11. [Testosterone treatment].Urologie (Heidelberg, Germany) · 2022
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Observational
  17. Review
  18. High prevalence of cardiometabolic risk features in adolescents with 47,XXY/Klinefelter syndrome.American journal of medical genetics. Part C, Seminars in medical genetics · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 1 country.

A M IsidoriDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
G BalerciaDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
A E CalogeroDepartment of Medical and Pediatric Sciences, University of Catania, Catania, Italy.
G CoronaMedical Department Endocrinology Unit, Maggiore-Bellaria Hospital, Bologna, Italy.
A FerlinDepartment of Medicine, University of Padua, Padua, Italy.
S FrancavillaDepartment of Life, Health and Environment Sciences, Andrology, and Epidemiology, University of L'Aquila, L'Aquila, Italy.
D SantiDepartment of Biosciences, Metabolism and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
M MaggiSexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139, Firenze, Italy. m.maggi@dfc.unifi.it.
Marche Polytechnic University · ITOspedale Bellaria · ITSapienza University of Rome · ITUniversity of Catania · ITUniversity of Florence · ITUniversity of L'Aquila · ITUniversity of Modena and Reggio Emilia · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe developed clinical practice guidelines to assess the individual risk-benefit profile of androgen replacement therapy in adult male hypogonadism (HG), defined by the presence of specific signs and symptoms and serum testosterone (T) below 12 nmol/L.

participantsThe task force consisted of eight clinicians experienced in treating HG, selected by the Italian Society of Endocrinology (SIE). The authors received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by a systematic review of controlled trials conducted on men with a mean T < 12 nmol/L and by interactive discussions. The guidelines were reviewed and sequentially approved by the SIE Guidelines Commission and Executive Committee.

conclusionsWe recommend T supplementation (TS) for adult men with severely reduced T levels (T < 8 nmol/L) to improve body composition and sexual function. We suggest that TS be offered to subjects with T < 12 nmol/L to improve glycaemic control, lipid profile, sexual function, bone mineral density, muscle mass and depressive symptoms, once major contraindications have been ruled out. We suggest that lifestyle changes and other available interventions (e.g. for erectile dysfunction) be suggested prior to TS. We suggest that TS should be combined with currently available treatments for individuals at high risk for complications, such as those with osteoporosis and/or metabolic disorders. We recommend against using TS to improve cardiac outcome and limited mobility. We recommend against using TS in men with prostate cancer, unstable cardiovascular conditions or elevated haematocrit. The task force places a high value on the timely treatment of younger and middle-aged subjects to prevent the long-term consequences of hypoandrogenism.

Indexed as

AdultAndrogensEndocrinologyHormone Replacement TherapyHumansHypogonadismItalyMalePractice Guidelines as TopicRandomized Controlled Trials as TopicSocieties, MedicalTreatment OutcomeAndrogens

Identifiers

PMID25384570
PMCPMC4282686
OpenAlexW2070369202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.